← Back to Search

Nonsteroidal Anti-inflammatory Drug

Aspirin 162 mg for Pre-eclampsia (ASPREO Trial)

Phase 2 & 3
Waitlist Available
Led By farah Amro, MD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-7 months
Awards & highlights

ASPREO Trial Summary

This trial studies if a daily aspirin can reduce preeclampsia risk in obese pregnant women with pre-existing conditions.

Eligible Conditions
  • Pre-eclampsia
  • Hypertension
  • Obesity

ASPREO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-7 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Preeclampsia diagnosis
Secondary outcome measures
Maternal Outcomes-Eclampsia
Maternal Outcomes-Gestational Hypertension
Maternal Outcomes-HELLP syndrome
+13 more

ASPREO Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 162 mg/day AspirinExperimental Treatment1 Intervention
Group II: 81 mg/day AspirinActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetylsalicylic acid
FDA approved

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
903 Previous Clinical Trials
320,757 Total Patients Enrolled
farah Amro, MDPrincipal InvestigatorUniversity of Texas Health Science Center of Houston

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
Farah Hassan Amro 2019. "Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03961360.
All > Preeclampsia > Durlaza
~37 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top